The company develops targeted immuno‑oncology biologics—including ligand‑directed antibody‑drug conjugates, engineered cytokine‑fusion proteins, and bispecific T‑cell engagers—that bind tumor‑associated antigens and reprogram the tumor microenvironment to enhance anti‑tumor immunity. It couples these therapeutics with a cloud‑based biomarker analytics suite that integrates multiplex IHC, single‑cell RNA‑seq, and circulating tumor DNA data to guide patient selection and dose optimization. The platform is offered to pharmaceutical, biotech, and academic partners developing oncology pipelines.
Funding
Funding not disclosed
Founders
Product
Problem
Many solid tumors exhibit heterogeneous antigen expression and an immunosuppressive tumor microenvironment (TME), which limits the efficacy of conventional chemotherapy and monotherapy immuno‑oncology agents. Consequently, patients often experience suboptimal response rates and significant off‑target toxicities.
Solution
The company engineers targeted, immune‑mediated therapeutics that simultaneously engage tumor‑specific antigens and remodel the TME to favor anti‑tumor immunity. Its pipeline includes ligand‑directed conjugates, engineered cytokine fusions, and bispecific antibodies designed to activate cytotoxic lymphocytes while reprogramming suppressive myeloid populations. By integrating predictive biomarkers and adaptive clinical‑trial designs, the platform accelerates dose optimization and patient selection for combination regimens. Preclinical models demonstrate enhanced tumor infiltration of CD8⁺ T cells and reduced regulatory T‑cell activity, supporting a mechanistic rationale for synergistic use with checkpoint inhibitors. The company also provides a cloud‑based analytics suite that aggregates pharmacodynamic readouts, enabling real‑time decision making across development programs.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oncology pipelines, as well as academic research groups and contract research organizations seeking targeted immuno‑oncology agents and companion biomarker services.
Features
- Ligand‑directed antibody‑drug conjugates that deliver cytotoxic payloads to validated tumor‑associated antigens with sub‑nanomolar affinity
- Engineered cytokine‑fusion proteins (e.g., IL‑2 variants) that selectively expand effector T cells and repolarize tumor‑associated macrophages toward a pro‑inflammatory phenotype
- Bispecific T‑cell engagers that bridge CD3 on T cells with tumor‑specific epitopes, facilitating antigen‑independent cytotoxic synapse formation
- Integrated biomarker platform combining multiplex immunohistochemistry, single‑cell RNA‑seq, and circulating tumor DNA to stratify patients and monitor TME dynamics
- Adaptive Phase 1/2 trial architecture with Bayesian dose‑escalation and seamless cohort expansion for rapid go/no‑go decisions
- Modular GMP manufacturing pipeline enabling scalable production of diverse biologic formats within a unified facility
- Secure, cloud‑based data dashboard that visualizes pharmacokinetic/pharmacodynamic trends, immune profiling, and efficacy endpoints for investigators and partners